These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 8381000)
1. Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds. Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R Biochem Pharmacol; 1993 Jan; 45(1):101-11. PubMed ID: 8381000 [TBL] [Abstract][Full Text] [Related]
2. Ca2+ ionophore A23187-stimulated secretion of azurophil granules in human polymorphonuclear leukocytes is largely mediated by endogenously formed leukotriene B4. Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R Biochem Pharmacol; 1994 Jul; 48(1):31-9. PubMed ID: 8043028 [TBL] [Abstract][Full Text] [Related]
3. Inversely-correlated inhibition of human 5-lipoxygenase activity by BAY X1005 and other quinoline derivatives in intact cells and a cell-free system--implications for the function of 5-lipoxygenase activating protein. Hatzelmann A; Goossens J; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R Biochem Pharmacol; 1994 Jun; 47(12):2259-68. PubMed ID: 8031320 [TBL] [Abstract][Full Text] [Related]
4. In vitro pharmacology of BAY X1005, a new inhibitor of leukotriene synthesis. Fruchtmann R; Mohrs KH; Hatzelmann A; Raddatz S; Fugmann B; Junge B; Horstmann H; Müller-Peddinghaus R Agents Actions; 1993 Mar; 38(3-4):188-95. PubMed ID: 8213345 [TBL] [Abstract][Full Text] [Related]
5. BAY X1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics. Müller-Peddinghaus R; Fruchtmann R; Ahr HJ; Beckermann B; Bühner K; Fugmann B; Junge B; Matzke M; Kohlsdorfer C; Raddatz S J Lipid Mediat; 1993; 6(1-3):245-8. PubMed ID: 8395246 [TBL] [Abstract][Full Text] [Related]
6. (R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl] acetic acid (BAY x1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. Gorenne I; Labat C; Gascard JP; Norel X; Müller-Peddinghaus R; Mohrs KH; Taylor WA; Gardiner PJ; Brink C J Pharmacol Exp Ther; 1994 Feb; 268(2):868-72. PubMed ID: 8114000 [TBL] [Abstract][Full Text] [Related]
7. Lung cancer cell lines inhibit leukotriene B4 production by human polymorphonuclear leukocytes at the level of phospholipase A2. Abe M; Matsuki H; Domae M; Kuwata H; Kudo I; Nakanishi Y; Hara N; Mitsuyama T; Furukawa T Am J Respir Cell Mol Biol; 1996 Nov; 15(5):565-73. PubMed ID: 8918363 [TBL] [Abstract][Full Text] [Related]
8. Studies of the inhibitory activity of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)-indol- 2-yl]-2,2-dimethyl propanoic acid) on arachidonic acid metabolism in human phagocytes. Ménard L; Laviolette M; Borgeat P Can J Physiol Pharmacol; 1992 Jun; 70(6):808-13. PubMed ID: 1423024 [TBL] [Abstract][Full Text] [Related]
9. Tenidap inhibits 5-lipoxygenase product formation in vitro, but this activity is not observed in three animal models. Carty TJ; Sweeney FJ; Griffiths RJ; Eskra JD; Ernest MJ; Pillar JS; Cheng JD; Loose LD; Joseph PA; Pazoles PP; Moore PF; Nagahisa A; Murase S; Kadin SB Inflamm Res; 1997 May; 46(5):168-79. PubMed ID: 9197987 [TBL] [Abstract][Full Text] [Related]
10. Mode of action of the leukotriene synthesis (FLAP) inhibitor BAY X 1005: implications for biological regulation of 5-lipoxygenase. Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Matzke M; Pleiss U; Keldenich J; Müller-Peddinghaus R Agents Actions; 1994 Nov; 43(1-2):64-8. PubMed ID: 7741044 [TBL] [Abstract][Full Text] [Related]
19. Metabolism of arachidonic acid by peripheral and elicited rat polymorphonuclear leukocytes. Formation of 18- and 19-oxygenated dihydro metabolites of leukotriene B4. Powell WS; Gravelle F J Biol Chem; 1990 Jun; 265(16):9131-9. PubMed ID: 2160957 [TBL] [Abstract][Full Text] [Related]
20. Linoleic acid and dihomogammalinolenic acid inhibit leukotriene B4 formation and stimulate the formation of their 15-lipoxygenase products by human neutrophils in vitro. Evidence of formation of antiinflammatory compounds. Iversen L; Fogh K; Bojesen G; Kragballe K Agents Actions; 1991 Jul; 33(3-4):286-91. PubMed ID: 1659156 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]